# A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833

> **NCT05364255** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 6 (actual)

## Conditions studied

- ER-positive, HER2-negative Breast Cancer

## Interventions

- **DRUG:** [14C]AZD9833 Oral Solution, 75 mg

## Key facts

- **NCT ID:** NCT05364255
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-10
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-06-20
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05364255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05364255, "A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05364255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*